Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $87000.0.

  • Guided Therapeutics' Cash & Equivalents fell 5515.46% to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year decrease of 5515.46%. This contributed to the annual value of $388000.0 for FY2024, which is 3434.86% down from last year.
  • Guided Therapeutics' Cash & Equivalents amounted to $87000.0 in Q3 2025, which was down 5515.46% from $185000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Cash & Equivalents registered a high of $2.7 million during Q3 2022, and its lowest value of $87000.0 during Q3 2025.
  • In the last 5 years, Guided Therapeutics' Cash & Equivalents had a median value of $591000.0 in 2023 and averaged $828421.1.
  • As far as peak fluctuations go, Guided Therapeutics' Cash & Equivalents soared by 583809.52% in 2021, and later plummeted by 7974.96% in 2024.
  • Over the past 5 years, Guided Therapeutics' Cash & Equivalents (Quarter) stood at $643000.0 in 2021, then surged by 259.72% to $2.3 million in 2022, then tumbled by 74.45% to $591000.0 in 2023, then tumbled by 34.35% to $388000.0 in 2024, then tumbled by 77.58% to $87000.0 in 2025.
  • Its Cash & Equivalents stands at $87000.0 for Q3 2025, versus $185000.0 for Q2 2025 and $115000.0 for Q1 2025.